Of concern is the development of autoimmunity due to D-penicillamine use, as evidenced by the new appearance of serum anti-nuclear antibodies (ANA) with variable titers, to be differentiated from increased ANA titers occasionally found already before the start of drug therapy attributed to Wilson disease itself [140]. Here, BTG3 is linked to Wilson disease.